AU2001281814A1 - Method for the selective survival or selective growth of a target cell by the use of a conjugate, its use in therapeutics and/or diagnostics and the preparationof said conjugate - Google Patents

Method for the selective survival or selective growth of a target cell by the use of a conjugate, its use in therapeutics and/or diagnostics and the preparationof said conjugate

Info

Publication number
AU2001281814A1
AU2001281814A1 AU2001281814A AU8181401A AU2001281814A1 AU 2001281814 A1 AU2001281814 A1 AU 2001281814A1 AU 2001281814 A AU2001281814 A AU 2001281814A AU 8181401 A AU8181401 A AU 8181401A AU 2001281814 A1 AU2001281814 A1 AU 2001281814A1
Authority
AU
Australia
Prior art keywords
conjugate
target cell
selective
present
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001281814A
Inventor
Jacques Fastrez
Patrice Soumillion
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Catholique de Louvain UCL
Original Assignee
Universite Catholique de Louvain UCL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Catholique de Louvain UCL filed Critical Universite Catholique de Louvain UCL
Publication of AU2001281814A1 publication Critical patent/AU2001281814A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention is in particular related to a method for the selective survival or selective growth of a target cell comprising the steps of: a) contacting the target cell with a conjugate compound A-B, wherein A is a selective antibody or antibody derivative recognizing the target cell and B is a biotic agent able to at least partially inactivate an anti-bios agent, said anti-bios agent is able to inhibit the growth of cells; and b) contacting the target cell with the anti-bios agent. The present invention also relates to said conjugate on its own, a selection medium for cells comprising said conjugate and cells that are selected or recognized using a method or conjugate according to the present invention. The present invention further elucidates a pharmaceutical compound or composition, a kit for the detection of a target cell or for the diagnosis of diseases caused by the target cell or a product that can be used in the therapy of infectious related diseases comprising a conjugate according to present invention.
AU2001281814A 2000-06-21 2001-06-07 Method for the selective survival or selective growth of a target cell by the use of a conjugate, its use in therapeutics and/or diagnostics and the preparationof said conjugate Abandoned AU2001281814A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00870139 2000-06-21
EP00870139 2000-06-21
PCT/EP2001/006439 WO2001097854A2 (en) 2000-06-21 2001-06-07 Method for the selective survival or selective growth of a target cell by the use of a conjugate, its use in therapeutics and/or diagnostics

Publications (1)

Publication Number Publication Date
AU2001281814A1 true AU2001281814A1 (en) 2002-01-02

Family

ID=8175770

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001281814A Abandoned AU2001281814A1 (en) 2000-06-21 2001-06-07 Method for the selective survival or selective growth of a target cell by the use of a conjugate, its use in therapeutics and/or diagnostics and the preparationof said conjugate

Country Status (8)

Country Link
US (1) US6969593B2 (en)
EP (1) EP1303635B1 (en)
AT (1) ATE354669T1 (en)
AU (1) AU2001281814A1 (en)
DE (1) DE60126776T2 (en)
DK (1) DK1303635T3 (en)
ES (1) ES2282281T3 (en)
WO (1) WO2001097854A2 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451995B1 (en) * 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
JP2002511857A (en) * 1997-06-11 2002-04-16 ザ スクール オブ ファーマシー ユニヴァーシティ オブ ロンドン Pharmaceutical compositions comprising an antibody-enzyme conjugate in combination with a prodrug

Also Published As

Publication number Publication date
WO2001097854A3 (en) 2002-04-11
US6969593B2 (en) 2005-11-29
DE60126776D1 (en) 2007-04-05
EP1303635A2 (en) 2003-04-23
ES2282281T3 (en) 2007-10-16
ATE354669T1 (en) 2007-03-15
US20030099658A1 (en) 2003-05-29
DK1303635T3 (en) 2007-06-04
EP1303635B1 (en) 2007-02-21
DE60126776T2 (en) 2007-10-31
WO2001097854A2 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
AU9536898A (en) 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the holesterin-ester transfer protein
WO2004087896A3 (en) Hepatocyte differentiation of stem cells
DE69630455D1 (en) PRODUCTION OF BETA -GLUKAN-MANNAN PREPARATIONS BY AUTOLYSIS OF CELLS UNDER SPECIFIC pH, TEMPERATURE AND TIME CONDITIONS
IE45086L (en) Amino acids.
WO2001022285A3 (en) A probabilistic record linkage model derived from training data
HK1062029A1 (en) Multiplication of viruses in a cell culture
EP1276486B8 (en) Joint repair using mesenchymal stem cells
WO2003042384A1 (en) Inducer for differentiation of embryo stem cells into ectodermal cells, method of obtaining the same and use thereof
EP0670369A3 (en) A novel peptide related to human programmed cell death and DNA encoding it
EP1367899A4 (en) Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
CA2132993A1 (en) Physiologically Active Substance
MY124527A (en) 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases
AU2002248384A1 (en) Serpin drugs for treatment of hiv infection and method of use thereof
WO2003046009A1 (en) ANTI-IL13 RECEPTOR α1 NEUTRALIZING ANTIBODY
DK208987A (en) POLYPEPTIDES AND ANTIBODIES CHARACTERISTIC FOR PAPILLOMVIRUS AND THEIR USE IN DIAGNOSTIC METHODS AND IN VACCINES
AU2001234273A1 (en) Thiazolopyrimidines and their use as modulators of chemokine receptor activity
DK0727489T3 (en) DNA sequence encoding an A. thaliana protein with delta-5,7-sterol, delta-7 reductase activity, delta-7Red protein, method of preparation, transformed yeast strains, uses
WO2002024697A1 (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
AU2001281814A1 (en) Method for the selective survival or selective growth of a target cell by the use of a conjugate, its use in therapeutics and/or diagnostics and the preparationof said conjugate
CA2239282A1 (en) Fused isoindolones as inhibitors of protein kinase c
MXPA05011435A (en) 5-hydroxyindoles with n-oxide groups and use thereof as a phosphodiesterase 4 inhibitor.
MXPA02010028A (en) Hypotensors.
AU6464699A (en) Labeling, immobilisation, enrichment, purification and detection of cells using specific domains that bind to the cell walls (cbd) of proteins binding to the drawn cell walls of viruses, bacteria or eukaryotic cells
AU6176596A (en) Compositions exhibiting adp-ribosyltransferase activity and methods for the preparation and use thereof
WO2002074921A3 (en) Methods for isolating proteins expressed by dendritic cells